Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

President Donald Trump's tariff policies have made Indy small store owners get creative. Some are stocking fewer products or raising prices.

Here are some highlights from the first half of the year: ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

It brings Lilly's total investment in Raheen to $2 billion, doubling the investment the company announced in March 2023.

Nina T Hovland, vice president and general manager of Novo Nordisk Ireland, Caitriona Walsh, country president and managing ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

Beyond that, Eli Lilly has a total of 11 pipeline projects in treating obesity, according to the company's CEO, David Ricks. This field will explode through the end of the decade, according to ...

Two former Eli Lilly executives and their families will ... from 2008-2017 before handing over the reins to current CEO Dave Ricks. “Our families share a commitment to advancing the future ...